Tilak Healthcare raises €2.5 million from iBionext Growth Fund
Paris, March 28th 2017 - Tilak Healthcare, a start-up from the iBionext network developing medical video games for both the diagnosis and follow-up of chronic diseases, today announced a funding of €2.5 million from iBionext Growth Fund.
The funds will help the company accelerate the development of its therapeutic mobile games, first targeting the ophthalmology field, with macular diseases. This alliance of digital innovation and clinical expertise is unique in the medical videogames world: it will allow Tilak Healthcare to offer screening and prevention solutions, thus leading to a better follow-up of many chronic diseases.
Edouard Gasser, CEO of Tilak Healthcare, was thrilled to comment: “At Tilak , we are proud to adapt the power of videogames and entertainment to healthcare, thanks to our very distinctive positioning in the digital health world. With the support of iBionext Growth Fund, we’ll make mobile gaming a great healthcare tool.”
Alexia Perouse, CEO of iBionext Growth Fund, stated: “We strongly believe in Tilak Healthcare’s potential. The complete recruitment of the team marks the acceleration of the deployment of Tilak’s platform towards doctors and patients, it shows positive signals for our investment. The alliance of videogames and medicine offers great potential to make Tilak Healthcare a leader in therapeutic mobile games.”
About Tilak Healthcare
Cofounded with iBionext in May 2016, Tilak Healthcare is one of the youngest start-ups of the iBionext ecosystem. It is specialized in digital healthcare and focusing on the development of a platform of medically-prescribed disruptive videogames for the monitoring and follow-up of patients suffering from chronic diseases.The company’s first application will target ophthalmology with macular diseases, which affect a large number of patients in the aging populations of developed countries. Tilak’s objective is to improve the management of these diseases and optimize the healthcare process.
Created in 2015, iBionext is a management company dedicated to the development of innovative healthcare start-ups. This initiative, launched as a network of start-ups by Bernard Gilly in 2012, aims to transform disruptive scientific ideas into innovative start-ups in the fields of biotech, medtech and connected medical devices. The start-ups are all located in a single site named “Passage de l’innovation” in Paris, France.
Since 2012, the iBionext network has participated in the creation of 8 companies - Pixium Vision (Euronext: PIX) GenSight Biologics (Euronext: SIGHT), Gecko Biomedical, Chronocam, ChronoLife, BrainEver, Tilak Healthcare, Brainiac - and raised over €250M (including €50M from iBionext Growth Fund). Six clinical trials are currently underway in the world and 140 collaborators specialized in various sectors have joined these companies.
IBionext Growth Fund was created in 2016 to fund and build new companies selected from the iBionext network.
For more information: http://ibionext.com/